ReviewsProdrugs of nucleoside analogues for improved oral absorption and tissue targeting
Section snippets
INTRODUCTION
Nucleosides are building blocks of RNA and DNA. Nucleoside analogues are synthetic compounds that are structurally similar to natural nucleosides. Many nucleoside analogues have antiviral and antitumor properties. Over the last two decades, numerous nucleoside analogues and their prodrugs were developed for the treatment of patients with infections of human immunodeficiency virus (HIV), including zidovudine (AZT), didanosine (ddI), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), abacavir,
RATIONALE FOR PRODRUG DESIGN
For orally administered drugs, the intestinal epithelial membrane forms the first barrier to drug absorption. Therefore, for a drug to be well absorbed in the gastrointestinal tract, it needs to possess optimum physicochemical properties in order to cross the epithelial membrane by passive diffusion. Prodrug strategies are typically employed to alter lipophilicity, permeability, stability, and tissue specificity of the active drugs and thus improve drug delivery properties over the parent drug.
SCREENING PARADIGMS FOR PRODRUGS
The effectiveness of a prodrug is typically evaluated by characterization of physicochemical properties, assessment of Caco‐2 cell permeabilities and determination of pharmacokinetics (PK) and exposures in animals. Considering the data from these screening studies and additional factors, such as, ease of synthesis, cost, and toxicity of the promoiety, lead prodrugs are selected for further evaluation. Figure 2 shows the screening paradigm used in our lab for prodrugs intended to improve oral
Prodrugs of Acyclic Nucleoside Analogues
Acyclovir, ganciclovir, penciclovir, and H2G are acyclic guanosine nucleoside analogues and have potent antiviral activities (Fig. 3). They are selectively phosphorylated to the monophosphate level by a virus specified thymidine kinase and subsequently converted to di‐ and triphosphates by cellular kinases.72., 73., 74. After phosphorylation, the triphosphates either incorporate into the viral DNA resulting in chain termination or slow the elongation of viral DNA and therefore, inhibit the
CONCLUSION
Drug development efforts have been made to continually identify new therapeutic agents and prodrugs with desired drug‐like characteristics, improved therapeutic efficacy and less adverse effects. For orally administered drugs, the intestinal epithelial membrane forms the first barrier to drug absorption. Most oral drugs are absorbed into systemic circulation by passive diffusion across the intestinal epithelial membrane. Since nucleoside analogues are polar molecules and have limited membrane
REFERENCES (187)
Antiviral drugs in current clinical use
J Clin Virol
(2004)- et al.
Capecitabine: A review
Clin Ther
(2005) - et al.
Involvement of multiple transporters in the oral absorption of nucleoside analogues
Adv Drug Deliv Rev
(1999) - et al.
Prodrug strategies in the design of nucleoside and nucleotide antiviral therapeutics
Annu Rep Med Chem
(2004) - et al.
Nucleoside transport in normal and neoplastic cells
Adv Enzyme Regul
(1993) - et al.
Nucleoside transporters: Molecular biology and implications for therapeutic development
Mol Med Today
(1999) - et al.
Structural modifications at the 2′‐ and 3′‐positions of some pyrimidine nucleosides as determinants of their interaction with the mouse erythrocyte nucleoside transporter
Biochem Pharmacol
(1984) Improved passive oral drug delivery via prodrugs
Adv Drug Deliv Rev
(1996)- et al.
Enzymes involved in the bioconversion of ester‐based prodrugs
J Pharm Sci
(2006) - et al.
Prodrug strategies based on intramolecular cyclization reactions
J Pharm Sci
(1997)